Form 4: Nuvation Bio Inc. Executive Stacy Markel Reports Stock Option Grant
SEC Form 4 Filing
Stacy Markel, Chief People Officer of Nuvation Bio Inc., reports the acquisition of stock options and shares under the company's employee stock purchase plan.
Summary
- Stacy Markel, Chief People Officer of Nuvation Bio Inc., filed a Form 4 detailing changes in beneficial ownership.
- On February 29, 2024, Markel acquired options to purchase 500,000 shares of Class A Common Stock at an exercise price of $1.87.
- These options vest 25% on the one-year anniversary of the grant date and then monthly over the following 36 months, contingent upon continued service.
- Markel also reported owning 10,591 shares of Class A Common Stock, which includes 3,000 shares acquired on May 19, 2023, and 3,000 shares acquired on November 17, 2023, under the company's 2021 Employee Stock Purchase Plan.
Sentiment
Score: 6
Explanation: The document is a routine regulatory filing, indicating standard executive compensation practices. It is neither particularly positive nor negative.
Positives
- The grant of stock options to the Chief People Officer aligns her interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the executive.
Industry Context
Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. This filing indicates standard executive compensation practices.
Comparison to Industry Standards
- Stock option grants are a common component of executive compensation packages in the biotechnology industry.
- Vesting schedules of four years with a one-year cliff are also typical.
- The size of the grant should be compared to similar companies and executive roles to determine if it is in line with industry standards.
Stakeholder Impact
- The stock option grant aligns the executive's interests with those of the shareholders, potentially incentivizing performance that benefits shareholders.
- Employees may view the grant as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 2023-05-19 | 3,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan |
| 2023-11-17 | 3,000 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan |
| 2024-02-29 | Grant date of stock options for 500,000 shares and transaction date |
| 2024-02-29 | First vesting date of the stock options (25% vests on the one-year anniversary) |
| 2034-02-27 | Expiration date of the stock options |
| 2024-03-04 | Date of Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.